As Lyrica patent expiry looms, Pfizer buys Array for $11.4bnPfizer has a made a $48 per share play for Array Biopharma, which values the cancer specialist at Share XAs Lyrica patent expiry looms, Pfizer buys Array for $11.4bnhttps://pharmaphorum.com/news/as-lyrica-patent-expiry-looms-pfizer-buys-array-for-11-4bn/
Roche delays Spark merger again amid reviews in US and UKRoche’s $4.3 billion takeover of US gene therapy specialist Spark Therapeutics has been pushed back again because regulators Share XRoche delays Spark merger again amid reviews in US and UKhttps://pharmaphorum.com/news/roche-delays-spark-merger-again-amid-reviews-in-us-and-uk/
Nine for 2019: Challenges impacting pharmaAs we move close to 2019’s halfway point, it’s time to reflect on the issues that are shaping Share XNine for 2019: Challenges impacting pharmahttps://pharmaphorum.com/r-d/views-analysis-r-d/nine-for-2019-challenges-impacting-pharma/
Merck & Co to buy cancer biotech Peloton for $2.2bnMerck & Co is to buy the privately-held biotech Peloton for up to $2.2 billion, adding further oncology Share XMerck & Co to buy cancer biotech Peloton for $2.2bnhttps://pharmaphorum.com/news/merck-co-to-buy-cancer-biotech-peloton-for-2-2bn/
Amryt to expand rare disease portfolio with $311m Aegerion mergerRare disease specialist Amryt Pharma plans to expand its rare disease portfolio with the acquisition of troubled Aegerion Share XAmryt to expand rare disease portfolio with $311m Aegerion mergerhttps://pharmaphorum.com/news/amryt-to-expand-rare-disease-portfolio-with-311m-aegerion-merger/
Takeda to sell dry eye drug to Novartis for up to $5.3bnTakeda has announced it is to sell the dry eye drug Xiidra to Novartis, and a surgical patch Share XTakeda to sell dry eye drug to Novartis for up to $5.3bnhttps://pharmaphorum.com/news/takeda-to-sell-dry-eye-drug-to-novartis-for-up-to-5-3bn/
Pfizer acquires Therachon and its dwarfism drugPfizer has announced it will pay $340 million upfront to snap up rare disease biotech Therachon, which is Share XPfizer acquires Therachon and its dwarfism drughttps://pharmaphorum.com/news/pfizer-acquires-therachon-and-its-dwarfism-drug/
Digital health M&A ground to halt in Q1 amid US shutdownM&A (mergers and acquisitions) in digital health almost ground to a halt in Q1 this year, according to Share XDigital health M&A ground to halt in Q1 amid US shutdownhttps://pharmaphorum.com/news/digital-health-ma-ground-to-halt-in-q1-amid-us-government-shutdown/
Hu-manity.co acquires ‘deep data’ firm BetterpathHu-manity.co has acquired Betterpath, a New York-based firm that allows patients and other users to search, find, and Share XHu-manity.co acquires ‘deep data’ firm Betterpathhttps://pharmaphorum.com/news/hu-manity-co-acquires-deep-data-firm-betterpath/
